Being introduced in 2010, fingolimod was among the first oral therapies for relapsing
multiple sclerosis (MS). Since that time, postmarketing surveillance has noted several case …

We herein report the case of a 63-year-old man who presented with a 3-month history of a
cutaneous nodular lesion of his jaw, low grade fever, lethargy and progressive cognitive …

Background: Leukopenia, a rare adverse effect of Fingolimod therapy, paves the way for
opportunistic infections. In this study, we reported rare fingolimod associated cryptococcal …

Fingolimod is an oral medication approved by the Food and Drug Administration in 2009 for
the treatment of relapsing remitting multiple sclerosis (RRMS). Initial clinical trials did not …

Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous
system (CNS), with an estimated 2.3 million people being affected globally, and is a major …

Fingolimod is a multiple sclerosis disease-modifying therapy which sequestrates
lymphocytes in the lymph nodes, thereby reducing peripheral blood lymphocytes …

Cryptococcosis is a recognised opportunistic infection in immunocompromised patients. The
long-term adverse effect profile of fingolimod, an immunomodulating agent approved for use …

The use of immunomodulatory and immunosuppressive therapies in multiple sclerosis (MS)
has allowed practitioners to regulate MS disease activity, with the caveat that these potent …

Abstract Fingolimod (Gilenya, Novartis) is an oral sphingosine-1-phosphate analogue used
in the treatment of relapsing multiple sclerosis (MS). Fingolimod treatment is associated with …

Discussion With this case, 11 patients with cryptococcosis meningitis with fingolimod have
been reported so far. To the best of our knowledge, this case is the second only report of …